|
|
CA19-9与非小细胞肺癌预后的相关性
|
Abstract:
血清糖类抗原19-9 (简称CA19-9)是一种粘蛋白类糖蛋白肿瘤标志物，是细胞膜的一种糖脂，是迄今报道的对胰腺癌敏感性最高的标志物。后来发现CA19-9也存在于其他恶性肿瘤中，如非小细胞肺癌、乳腺癌和卵巢癌等。以往文献提示，CA19-9的表达水平在非小细胞肺癌不同的病理分型、临床分期、疗效及预后方面中可能存在差异。因此，就CA19-9在临床中对于癌症患者的诊治及预后方面的相关文献进行综述，重点阐释在非小细胞肺癌预后评估中的价值，为临床中针对CA19-9升高的非小细胞肺癌的个体化诊疗和全程管理提供参考。
Serum carbohydrate antigen 19-9 (CA19-9 for short) is a mucin-type carbohydrate protein tumor marker, which is a glycolipid on cell membrane. It is the most sensitive marker for pancreatic can-cer reported so far. Later studies found that CA19-9 also exists in other malignancies, such as non-small cell lung cancer, breast cancer, ovarian cancer, etc. Previous literature suggests that the expression level of CA19-9 in non-small cell lung cancer may be different in terms of pathological classification, clinical staging, efficacy and prognosis. Therefore, a review of relevant literature on the diagnosis, treatment, and prognosis of cancer patients with CA19-9 in clinical practice is con-ducted, with a focus on elucidating its value in evaluating the prognosis of non-small cell lung cancer, providing reference for individualized diagnosis, treatment, and overall management of non-small cell lung cancer with elevated CA19-9 in clinical practice.
| [1] | Yang, D., Liu, Y., Bai, C., et al. (2020) Epidemiology of Lung Cancer and Lung Cancer Screening Rograms in China and the United States. Cancer Letters, 468, 82-87. https://doi.org/10.1016/j.canlet.2019.10.009 |
| [2] | Cao, M. and Chen, W. (2019) Epidemiology of Lung Cancer in China. Thoracic Cancer, 10, 3-7.
https://doi.org/10.1111/1759-7714.12916 |
| [3] | Bade, B.C. and Cruz, C.S.D. (2020) Lung Cancer 2020: Epidemi-ology, Etiology, and Prevention. Clinics in Chest Medicine, 41, 1-24. https://doi.org/10.1016/j.ccm.2019.10.001 |
| [4] | Siegel, R.L., Miller, K.D., Fuchs, H.E., et al. (2021) Cancer Statis-tics, 2021. CA: A Cancer Journal for Clinicians, 71, 7-33. https://doi.org/10.3322/caac.21654 |
| [5] | 陈谦, 刘延国, 刘联, 等. 2021年非小细胞肺癌内科治疗进展[J]. 精准医学杂志, 2022, 37(1): 85-92. |
| [6] | Herbst, R.S., Mor-gensztern, D. and Boshoff, C. (2018) The Biology and Management of Non-Small Cell Lung Cancer. Nature, 553, 446-454. https://doi.org/10.1038/nature25183 |
| [7] | Wang, M., Herbst, R.S. and Boshoff, C. (2021) Toward Per-sonalized Treatment Approaches for Non-Small-Cell Lung Cancer. Nature Medicine, 27, 1345-1356. https://doi.org/10.1038/s41591-021-01450-2 |
| [8] | Luo, G., Jin, K., Deng, S., et al. (2021) Roles of CA19-9 in Pancreatic Cancer: Biomarker, Predictor and Promoter. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1875, Article ID: 188409.
https://doi.org/10.1016/j.bbcan.2020.188409 |
| [9] | Koprowski, H., Steplewski, Z., Mitchell, K., et al. (1979) Colo-rectal Carcinoma Antigens Detected by Hybridoma Antibodies. Somatic Cell Genetics, 5, 957-971. https://doi.org/10.1007/BF01542654 |
| [10] | Chen, Z., Huang, L. and Zhu, B. (2018) Assessment of Seven Clinical Tumor Markers in Diagnosis of Non-Small-Cell Lung Cancer. Disease Markers, 2018, Article ID: 9845123. https://doi.org/10.1155/2018/9845123 |
| [11] | Lin, Y.Y. and Cho, S.F. (2019) Occult Scar Carcinoma of the Lung with Overt Liver Metastases and High Serum CA 19-9 Levels. Journal of Postgraduate Medicine, 65, 251-252. https://doi.org/10.4103/jpgm.JPGM_145_19 |
| [12] | Nagami, H., Nohara, T., Yamauchi, M., et al. (1988) A Case of Two Patients with Primary Lung Cancer Secreting CA19-9. Nihon Geka Gakkai Zasshi, 89, 292-296. |
| [13] | Zeng, P., Li, H., Chen, Y., Pei, H.T. and Zhang, L.J. (2019) Serum CA19-9 Levels Are Significantly Increased in Patients Suffering from Liver, Lung, and Other Diseases. Progress in Molecular Biology and Translational Science, 162, 253-264. https://doi.org/10.1016/bs.pmbts.2018.12.010 |
| [14] | Lee, T., Teng, T.Z.J. and Shelat, V.G. (2020) Carbohydrate An-tigen 19-9—Tumor Marker: Past, Present, and Future. World Journal of Gastrointestinal Surgery, 12, 468-490. https://doi.org/10.4240/wjgs.v12.i12.468 |
| [15] | 赵雪梅, 迪娜尔. CA19-9检测对胰腺癌的诊断意义[J]. 新疆医学, 2010, 40(4): 73-75. |
| [16] | Azizian, A., Rühlmann, F., Krause, T., et al. (2020) CA19-9 for Detecting Recurrence of Pancreatic Cancer. Scientific Reports, 10, Article No. 1332. https://doi.org/10.1038/s41598-020-57930-x |
| [17] | Heger, U., Sun, H., Hinz, U., et al. (2020) Induction Chemo-therapy in Pancreatic Cancer: CA 19-9 May Predict Resectability and Survival. HPB, 22, 224-232. https://doi.org/10.1016/j.hpb.2019.06.012 |
| [18] | Li, J., Li, Z., Kan, H., et al. (2019) CA19-9 Elevation as an Indica-tion to Start Salvage Treatment in Surveillance after Pancreatic Cancer Resection. Pancreatology, 19, 302-306. https://doi.org/10.1016/j.pan.2019.01.023 |
| [19] | 中华人民共和国国家卫生健康委员会. 胰腺癌诊疗规范(2018年版) [J]. 临床肝胆病杂志, 2019, 35(2): 281-293. |
| [20] | Indellicato, R., Zulueta, A., Caretti, A. and Trinchera, M. (2020) Complementary Use of Carbohydrate Antigens Lewis a, Lewis b, and Sialyl-Lewis a (CA19-9 Epitope) in Gas-trointestinal Cancers: Biological Rationale towards a Personalized Clinical Application. Cancers, 12, Article 1509. https://doi.org/10.3390/cancers12061509 |
| [21] | Tsen, A., Barbara, M. and Rosenkranz, L. (2018) Dilemma of Ele-vated CA 19-9 in Biliary Pathology. Pancreatology, 18, 862-867. https://doi.org/10.1016/j.pan.2018.09.004 |
| [22] | Liu, F., Wang, J.K., Ma, W.J., et al. (2019) Clinical Value of Pre-operative CA19-9 Levels in Evaluating Resectability of Gallbladder Carcinoma. ANZ Journal of Surgery, 89, E76-E80. https://doi.org/10.1111/ans.14893 |
| [23] | Kim, S., Park, B.K., Seo, J.H., et al. (2020) Carbohydrate Antigen 19-9 El-evation without Evidence of Malignant or Pancreatobiliary Diseases. Scientific Reports, 10, Article No. 8820. https://doi.org/10.1038/s41598-020-65720-8 |
| [24] | Galle, P.R., Foerster, F., Kudo, M., et al. (2019) Biology and Significance of α-Fetoprotein in Hepatocellular Carcinoma. Liver International, 39, 2214-2229. https://doi.org/10.1111/liv.14223 |
| [25] | Welch, H.G. and Albertsen, P.C. (2020) Reconsidering Prostate Cancer Mortality—The Future of PSA Screening. The New England Journal of Medicine, 382, 1557-1563. https://doi.org/10.1056/NEJMms1914228 |
| [26] | Toshie, Y., Michael, G., Andrea, S.V., et al. (2018) ADAM10 Sheddase Activity Is a Potential Lung-Cancer Biomarker. Journal of Cancer, 9, 2559-2570. https://doi.org/10.7150/jca.24601 |
| [27] | Ajona, D., Okrój, M., Pajares, M.J., et al. (2018) Complement C4d-Specific Antibodies for the Diagnosis of Lung Cancer. Oncotarget, 9, 6346-6355. https://doi.org/10.18632/oncotarget.23690 |
| [28] | Xie, F., Xu, L., Mu, Y., et al. (2023) Diagnostic Value of Seven Autoantibodies Combined with CEA and CA199 in Non-Small Cell Lung Cancer. Clinical Laboratory, 69, 897-905. https://doi.org/10.7754/Clin.Lab.2022.220728 |
| [29] | 孙士芳, 陈众博, 张筠, 等. 肺泡灌洗液中CA72-4和CA19-9诊断肺癌的价值研究[J]. 中国全科医学, 2018, 21(6): 653-657. |
| [30] | 李星辰. 伴随CA19-9升高的非小细胞肺癌临床特征与预后分析[D]: [硕士学位论文]. 唐山: 华北理工大学, 2021. |
| [31] | 中华医学会检验医学分会肿瘤标志物专家委员会. 肿瘤标志物临床检测的基本原则[J]. 中华检验医学杂志, 2004, 35(2): 103-105. |
| [32] | Li, Y., Tian, X., Gao, L., et al. (2019) Clinical Significance of Circulating Tumor Cells and Tumor Markers in the Diagnosis of Lung Cancer. Cancer Medicine, 8, 3782-3792. https://doi.org/10.1002/cam4.2286 |
| [33] | 方高洁, 胡娟. 肿瘤标记物CEA, SCCA, CYFRA21-1联合NSE检测对肺癌的诊断价值分析[J]. 实用癌症杂志, 2019, 34(7): 1161-1163. |
| [34] | Fang, R., Zhu, Y., Khadka, V.S., et al. (2018) The Evaluation of Serum Biomarkers for Non-Small Cell Lung Cancer (NSCLC) Diagnosis. Frontiers in Physiology, 9, Article 1710. https://doi.org/10.3389/fphys.2018.01710 |
| [35] | Li, Q. and Sang, S. (2020) Diagnostic Value and Clinical Signifi-cance of Combined Detection of Serum Markers CYFRA21-1, SCC Ag, NSE, CEA and ProGRP in Non-Small Cell Lung Carcinoma. Clinical Laboratory, 66, 2189-2195.
https://doi.org/10.7754/Clin.Lab.2020.191243 |
| [36] | Jiang, Z.F., Wang, M. and Xu, J.L. (2018) Thymidine Kinase 1 Combined with CEA, CYFRA21-1 and NSE Improved Its Diagnostic Value for Lung Cancer. Life Sciences, 194, 1-6. https://doi.org/10.1016/j.lfs.2017.12.020 |
| [37] | Wang, X., Liao, X., Zhang, B., et al. (2021) An Electrochemical Immunosensor for the Detection of Carcinoembryonic Antigen Based on Au/gC3N4 NSs-Modified Electrode and CuCo/CNC as Signal Tag. Microchimica Acta, 188, Article No. 408. https://doi.org/10.1007/s00604-021-05013-7 |
| [38] | Wang, W.J., Tao, Z., Gu, W., et al. (2013) Clinical Observations on the Association between Diagnosis of Lung Cancer and Serum Tumor Markers in Combination. Asian Pacific Journal of Cancer Prevention, 14, 4369-4371.
https://doi.org/10.7314/APJCP.2013.14.7.4369 |
| [39] | Bilgin, E., Dizdar, Y., Serilmez, M., et al. (2013) For Which Cancer Types Can Neuron-Specific Enolase Be Clinically Helpful in Turkish Patients? Asian Pacific Journal of Cancer Prevention, 14, 2541-2544.
https://doi.org/10.7314/APJCP.2013.14.4.2541 |
| [40] | 张海生, 徐震. 血清 CA19-9？CA15-3？CEA？NES 联合检测对肺癌的诊断价值[J]. 实用癌症杂志, 2018, 33(12): 92-94. |
| [41] | Niklinski, J., Furman, M., Laudanski, J. and Ko-zlowski, M. (1992) Prognostic Value of Pretreatment CEA, SCC-Ag and CA 19-9 Levels in Sera of Patients with Non-Small Cell Lung Cancer. European Journal of Cancer Prevention, 1, 401-406. https://doi.org/10.1097/00008469-199210000-00002 |
| [42] | Chen, H., Fu, F., Zhao, Y., et al. (2021) The Prognostic Value of Preoperative Serum Tumor Markers in Non-Small Cell Lung Cancer Varies with Radiological Features and Histological Types. Frontiers in Oncology, 11, Article 645159. https://doi.org/10.3389/fonc.2021.645159 |
| [43] | 杨玲. 非小细胞肺癌患者血清中CD8+ T细胞, CEA及CA19-9水平与肿瘤转移的相关性分析[J]. 江西医药, 2020, 55(2): 218-221. |
| [44] | 陈莉娜, 燕存子, 加孜那？托哈依. 生物分子标志物在肺癌中的研究进展[J]. 新疆医学, 2018, 48(10): 1131-1136. |
| [45] | Jiang, C., Zhao, M., Hou, S., et al. (2022) The Indicative Value of Serum Tumor Markers for Metastasis and Stage of Non-Small Cell Lung Cancer. Cancers, 14, Article 5064. https://doi.org/10.3390/cancers14205064 |
| [46] | 杨园园, 史萍. 血清肿瘤标志物水平与非小细胞肺癌患者脑转移的相关性[J]. 河南医学研究, 2021, 30(4): 668-670. |
| [47] | 孙建超, 赵金鹏. 非小细胞肺癌患者化疗前后血清 CA19-9和肿瘤异常蛋白水平变化及意义[J]. 中国卫生工程学, 2021, 20(6): 1017-1018. |
| [48] | Yamada, T., Nakani-shi, Y., Okamura, K., et al. (2018) Impact of Serum Carbohydrate Antigen 19-9 Level on Prognosis and Prediction of Lymph Node Metastasis in Patients with Intrahepatic Cholangiocarcinoma. Journal of Gastroenterology and Hepatology, 33, 1626-1633. https://doi.org/10.1111/jgh.14124 |
